Orforglipron (Foundayo)

Orforglipron sits at the bottom of the worth-trying tier because it pairs genuinely strong, deep evidence and unmatched oral convenience with an effect size that loses to the injectables. For the indicated population, adults with obesity or weight-related metabolic disease, it is a legitimately good option: an effective, once-daily, needle-free GLP-1 with the largest launch evidence base in the class and a price below the shots. The honest caveats are that it is less powerful than injectable semaglutide or tirzepatide, that a dedicated cardiovascular outcomes trial is still years out, and that weight returns after stopping. Judge it as ongoing therapy, not a quick course.

✅ Best for: Adults with obesity, or overweight plus a metabolic condition, who want effective GLP-1 treatment without injections. People who cannot tolerate the strict fasting of oral semaglutide and want a pill they can take with food. Those who value access, cost, and adherence over squeezing out the last few percent of weight loss. Patients transitioning off an injectable GLP-1 who want an oral maintenance option, supported by the maintenance data in ATTAIN-MAINTAIN (2026). Anyone who will pair the drug with resistance training and adequate protein to protect lean mass.

❌ Avoid if: You have a personal or family history of medullary thyroid cancer or the MEN2 syndrome, an absolute contraindication for the GLP-1 class. You have had pancreatitis. You are pregnant or trying to conceive, since safety is not established. You are chasing maximum weight loss and will accept injections, where tirzepatide and injectable semaglutide do more. You take insulin or a sulfonylurea without medical supervision, given the added risk of low blood sugar shown in the diabetes trials, per Rosenstock 2025.